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ABSTRACT  
Background. Continuous positive airways pressure (CPAP) and high-flow nasal oxygen (HFNO) are considered ‘aerosol-
generating procedures’ (AGPs) in the treatment of COVID-19. We aimed to measure air and surface environmental 
contamination of SARS-CoV-2 virus when CPAP and HFNO were used, compared with supplemental oxygen, to 
investigate the potential risks of viral transmission to healthcare workers and patients. 
Methods. 30 hospitalised patients with COVID-19 requiring supplemental oxygen, with a fraction of inspired oxygen 
³0.4 to maintain oxygen saturations ³94%, were prospectively enrolled into an observational environmental sampling 
study. Participants received either supplemental oxygen, CPAP or HFNO (n=10 in each group).  A nasopharyngeal swab, 
three air and three surface samples were collected from each participant and the clinical environment. RT qPCR 
analyses were performed for viral and human RNA, and positive/suspected-positive samples were cultured for the 
presence of biologically viable virus.  
Results. Overall 21/30 (70%) of participants tested positive for SARS-CoV-2 RNA in the nasopharynx. In contrast, only 
4/90 (4%) and 6/90 (7%) of all air and surface samples tested positive (positive for E and ORF1a) for viral RNA 
respectively, although there were an additional 10 suspected-positive samples in both air and surfaces samples 
(positive for E or ORF1a). CPAP/HFNO use or coughing was not associated with significantly more environmental 
contamination compared with supplemental oxygen use. Only one nasopharyngeal sample was culture positive.  
Conclusions. The use of CPAP and HFNO to treat moderate/severe COVID-19 did not appear to be associated with 
substantially higher levels of air or surface viral contamination in the immediate care environment, compared with 
the use of supplemental oxygen.  
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KEY MESSAGES FOR BMJ THORAX 
 
What is the key question? 
Do hospitalised COVID-19 patients receiving treatment with CPAP and HFNO present a significant added risk of viral 
contamination to the surrounding environment used by healthcare workers? 
 
What is the bottom line?  
The use of CPAP or HFNO to treat moderate/severe COVID-19 did not produce significant additional air or surface viral 
contamination compared to supplemental oxygen.   
 
Why read on?  
The evolving evidence from hospitalised cases of SARS-CoV-2 infection and the risks of occupational/nosocomial 
exposure should prompt an evidence-based reassessment of infection-prevention and control measures for non-
invasive respiratory support treatments that are currently considered ‘aerosol generating procedures.’ 
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INTRODUCTION 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that has led to the 
global pandemic of Coronavirus disease 2019 (COVID-19), as declared by the World Health Organisation on 11th March 
2020. Transmission is by close contact, droplets (>5-10µm diameter) that deposit closer to their source, and airborne 
inhalation of aerosols (<5µm diameter) that suspend in the air for longer, travel further and have the potential to 
reach the alveolar region of the lung. Airborne transmission has historically been associated with the use of aerosol 
generating procedures (AGPs)1 2.   
UK data from 2020 estimated that 17% of all emergency COVID-19 admissions required respiratory support 
in high-dependency or intensive-care (ICU) settings, which included the use of non-invasive respiratory support and 
mechanical ventilation for moderate/severe cases (16% and 10% of all admissions respectively)3. Types of non-
invasive respiratory support commonly include the use of continuous positive airway pressure (CPAP) and high-flow 
nasal oxygen (HFNO) devices which have been associated with reductions in mortality and progression to intubation 
for hypoxemic respiratory failure in some studies4,5. Their effectiveness in the treatment of COVID-19 is currently under 
evaluation in randomised controlled trials. Both are widely designated as AGPs and necessitate additional airborne 
precautions including cohorting of patients and the use of FFP3 masks for healthcare workers (HCWs) to mitigate the 
risk of aerosol transmission6 7. However, this is based on weak evidence from the SARS-CoV-1 outbreak and may delay 
or restrict patient access to the use of these therapies 8.  Nosocomial transmission from earlier coronavirus outbreaks 
(SARS-CoV-1 and MERS-CoV) were reported as up to 80% and 40% for patients and HCWs respectively9 and recent 
studies suggest that HCWs represent a population with a substantial burden from COVID-19, particularly in non-ICU 
settings where airborne precautions are less frequently used10 11.  
  SARS-CoV-2 environmental contamination has been widely found in multiple studies, however very few have 
specifically evaluated the impact of CPAP and/or HFNO, or have found biologically viable virus that proves a 
transmission risk to HCWs12-20. Other studies in this field include aerosol generation studies that have mainly used 
patient simulators or healthy volunteers21-24. Here we report our observations from sampling the clinical environment 
of COVID-19 patients undergoing CPAP and HFNO, compared to the use of supplemental oxygen, to better understand 
the risks of airborne and fomite SARS-CoV-2 contamination and exposure to HCWs.  
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MATERIALS & METHODS 
Study design, participants and setting.  
This study was a prospective observational study of environmental viral contamination from hospital 
admissions with COVID-19 as part of the International Severe Acute Respiratory and emerging Infections Consortium 
(ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK, www.isaric4c.net). It was performed across three UK 
hospitals at University Hospitals Birmingham NHS Foundation Trust and study participants were NHS patients co-
enrolled (or who were eligible to be co-enrolled) into ISARIC WHO CCP-UK and the RECOVERY-Respiratory Support 
trial25. Participant inclusion criteria included having suspected or confirmed SARS-CoV-2 infection with hypoxaemia 
(defined as requiring supplemental oxygen with a fraction of inspired oxygen ³0.4 to maintain oxygen saturations 
³94%) and suitable for CPAP or HFNO. Participants were enrolled into one of three groups (n=10 per group); CPAP, 
HFNO or supplemental oxygen, within 5-days of commencing treatment. Recruitment was opportunistic and written 
informed consent was obtained before any study procedures were undertaken. The machines used to deliver CPAP 
were either a Philips Respironics Trilogy, V60 using ResMed AcuCare masks with Heat Moisture Exchange filter (HME), 
or the University College London (UCL) Ventura system with viral filters, and all were capable of flow rates from 15-
60L/min. HFNO was delivered by a Fisher and Paykel Airvo2 system using Optiflow nasal cannulae (OPT944) with a 
typical flow rate between 50-60L/minute. Participants received supplemental oxygen via a Venturi facemask with a 
maximal flow of 15L/min. The flow rate, inspired FiO2  and positive end expiratory pressures (PEEP) were set according 
to clinical need.   
Data and sample collection  
 Environmental samples were taken from the care setting of each participant, which varied according to 
clinical and operational needs. Basic demographic and clinical data were collected with samples in a single visit that 
lasted up to 60-minutes. Room temperature, humidity and carbon dioxide levels were recorded using a Therm 
M2000C Air Quality Monitor. Nasopharyngeal samples were collected using a mid-turbinate flocked swab in 
accordance with standard operating procedures and stored in viral transport medium (VTM).  Air samples were 
collected using a Coriolis micro (µ) air sampler (Bertin Technologies, France) that uses liquid cyclonic technology able 
to collect particles from 0.5µm in diameter16. The device inlet was aligned to the mouth of the participant at a distance 
of 50cms, and sampled the air on three occasions, each for 10-minutes at a flow rate of 300L/min (total 9m3 air). The 
first air sample was collected with the participant at rest with supplemental oxygen only. Where the participant was 
unable to tolerate removal of CPAP/HFNO for the first sample, this was collected on CPAP/HFNO in order to keep the 
sampling period consistent for all participants. The next air sample was with CPAP/HFNO in place for a minimum of 
5-minutes (or supplemental oxygen) and the third air sample involved the addition of voluntary coughing every 2-
minutes. All surface samples were taken from within 2m of the participant and used sterile flocked swabs (Coplan, 
US) pre-moistened with VTM to swab 25cm2 from the floor, the bed table and a high-object (above participant head 
height such as a light fitting), in accordance with WHO sampling guidance26. All swabs were placed into 1mLs VTM. 
Winslow et al; SARS-CoV-2 environmental contamination from hospitalised COVID-19 patients receiving aerosol-generating procedures. 
Page 6 of 17 
All samples were stored on ice for less than 2-hours before being stored at -80oC and later transported in accordance 
with UN3373 using chilled biotherm containers that maintained storage temperature at 4-6oC for laboratory analysis 
at Imperial College London.  
Detection and quantification of human and SARS-CoV-2 viral RNA by real-time polymerase chain reaction and 
viral cultures 
Laboratory analyses were performed blinded to study group. Viral RNA detection and quantification was 
performed using quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR), as described 
elsewhere16. In summary, samples were extracted from 200µL of the VTM medium using the QIAsymphony SP 
(Qiagen, Germany) instrument according to the manufacturer’s instructions and SARS-CoV-2 viral RNA was detected 
using AgPath-ID One-Step RT-PCR Reagents (Life Technologies) with specific primers and probes targeting the 
envelope (E)27 and ORF1a genes28. A standard curve with six serial dilutions of 1x105 – 1 x 100 copies/ul E gene was 
included in each run of the RT-qPCR. A sample was defined as positive for viral RNA if both E and ORF1a RT-qPCR 
assays gave cycle time (Ct) values <45. A Ct value <45 for only one of these viral gene targets was considered a 
suspected-positive result.  A one-step RT-qPCR assay targeting human RNaseP was used to indicate human biological 
material in nasopharyngeal and surface swabs29. Human biological material in air samples was quantified by a one-
step RT-qPCR assay targeting human 18s rRNA (18s rRNA_Forward 5’-GGTAACCCGTTGAACCCCAT-3’, 18s 
rRNA_Reverse 5’-CAACGCAAGCTTATGACCCG-3’, 18s rRNA_Probe 5’-FAM-GTGATGGGGATCGGGGATTG-BHQ1-3’). 
A sample was defined as positive for human RNA if the Ct value was <45. Vero E6 (African Green monkey kidney) cells 
expressing ACE2 and TMPRSS were used to culture virus from any positive/suspected positive viral RNA sample. Vero 
were maintained in DMEM supplemented with heat-inactivated foetal bovine serum (10%) and 
Penicillin/Streptomycin (10, 000 IU/mL &10, 000 µg/mL). For virus isolation, 200 µL of samples were added to 24 well 
plates. On day 0 and after 5-7 days the cell supernatants were collected, and RT-qPCR used to detect SARS-CoV-2 RNA 
as described above. Samples with at least one log increase in copy numbers for the E gene (reduced Ct values relative 
to the original samples) after 5-7 days propagation in cells compared with the starting value were considered positive 
by viral culture30. 
Statistical analyses.  
This was an exploratory study intended to be descriptive in nature, no formalised sample size was calculated, 
and a sample size of 30 was used to allow for some stability in the estimates (mean and standard deviation) of the 
outcomes31. Analysis of variance (ANOVA/Kruskal-Wallis, as appropriate) were used to provide an overall comparison 
of the three groups, and significant variations were further explored by pairwise comparisons (unpaired t-tests against 
the supplemental oxygen group). All statistical tests were two-tailed and a p-value<0.05 was considered statistically 
significant. The statistical tests were performed in SAS and Prism 7 (GraphPad Inc, USA). Statistically significant 
differences should be interpreted with caution as the study was not powered to detect differences in the treatment 
arms. 
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RESULTS 
32 eligible patients were invited to take part and two declined to participate (one CPAP and one supplemental 
oxygen). Samples from the 30 enrolled participants were collected between December 11, 2020, and February 19, 2021, 
when the dominant variant was likely to have been B.1.1.7. The study population demographics, clinical 
characterisation of COVID-19 disease, and environmental conditions of the care provided to them are presented in 
Table 1.  All participants required oxygen support on admission and commenced dexamethasone the same day. 
Participant demographics were comparable across the study groups. Participants from the HFNO group were sampled 
significantly later in their illness compared with those receiving supplemental oxygen (mean 16-days, 95%CI 13-19, vs 
mean 9-days, 95%CI 5-13, from symptom onset respectively) and participants receiving supplemental oxygen were 
sampled significantly earlier into their hospital stay (median 1-day, IQR 0-3, compared with CPAP median of 4.5-days, 
IQR 2-6, and HFNO median of 3-days, IQR 2-6) (sFig. 1). Similar proportions of patients in each study group were cared 
for in cohorted areas or side room settings. Participants receiving CPAP/HFNO were more commonly accommodated 
in negative-pressure rooms. Compared with patients receiving supplemental oxygen, the room air recordings 
measured significantly lower temperatures for HFNO, with lower CO2 content and humidity for CPAP (sFig. 2).   
Participants had detectable viral RNA in the nasopharynx at the time of environmental sampling. 
Overall 21/30 (70%) of participants tested positive for SARS-CoV-2 RNA in the nasopharynx at the time of 
environmental sampling (Table 2). An additional participant was a suspected-positive case and all study participants 
tested positive on PCR testing either in the community or on admission to hospital (data not shown). Ct values, as an 
inversely related measure or estimate of genetic quantity (meaning low Ct values are indicative of greater target gene 
quantity in the sample), were also analysed for all samples. For positive nasopharyngeal samples, the mean Ct value 
was 29.2 (95%CI 27-32) and were comparable across different study groups with high correlation between the Ct value 
for each gene (r2=0.95). There were no correlations between the Ct values of any viral genes and the duration of 
illness/hospital stay (sFig. 3). 
Low-levels of viral RNA in air samples, regardless of whether CPAP or HFNO was in use or if the participant was 
coughing. 
Overall 9/30 (30%) of participants had at least one positive or suspected-positive result from one or more of 
the three air samples collected (Fig. 1, sFig. 4 and sFig. 5). There were only 4/90 (4%) positive air samples, with an 
additional 10 suspected-positive. Furthermore, the Ct values for positive and suspected-positive air samples were 
substantially higher than paired samples in the nasopharynx, indicating minimal viral RNA in the air. The distribution 
of these positive and suspected-positive air samples did not indicate a relationship with the use of CPAP or coughing, 
but 7/14 (50%) of the positive and suspected-positive air samples were from the HFNO group despite only half of 
these participants testing positive for viral RNA on nasopharyngeal samples, although this was not statistically 
significant (Table 2, Fig. 1). Human 18s RNA was detectable in 85/90 (94%) of air samples. Again, the use of 
CPAP/HFNO and/or coughing did not appear to alter the quantity of human RNA. Post-hoc analyses explored 
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potential differences between the nine participants who had tested positive or suspected-positive for viral RNA in one 
or more of the air samples, compared with the other 21 participants with negative air samples. Irrespective of the use 
of CPAP/HFNO at rest or on coughing, we found no significant differences with the environmental variables, days 
unwell at time of sampling, or nasopharyngeal Ct values between those who did and did not have viral RNA in air 
samples.  
Clinical surfaces were more contaminated with viral RNA than the air samples 
A higher proportion, 14/30 (47%), of participants had at least one positive or suspected-positive sample for 
viral RNA from one or more of the three surface samples collected (Fig. 2, sFig. 6 and sFig. 7). Only four participants 
had a positive or suspected-positive sample in both an air and surface sample (two participants receiving 
supplemental oxygen and one from CPAP and HFNO). In total, 6/90 (7%) of surface swabs were positive for viral RNA; 
5/30 (17%) floor samples tested positive (and 4 suspected-positive), no table surface samples tested positive (and 3 
suspected-positive) and only one high-object surface sample tested positive (and 3 suspected-positives). As with our 
air samples, the Ct values for viral genes were greater than those recorded from the nasopharynx and there were no 
differences with the use of CPAP/HFNO on any surface type. The floor was the most frequently contaminated surface 
(30%) followed by the high-object surfaces (13%) and tables (10%). Human RNA could be detected in 28/30 (93%) 
floor samples, 16/30 (53%) table samples and only 10/30 (33%) high-object surface samples. The Ct values for human 
RNaseP steadily increased from nasopharyngeal samples to floor, table and then the high-object samples. As before, 
the subset of participants with one or more positive or suspected-positive surface sample for viral RNA (n=14) were 
compared against participants who had negative surface swabs (n=16). The Ct values for viral RNA did not appear to 
vary significantly with the number of days unwell or nasopharyngeal Ct values between those who did and did not 
have viral RNA in surface samples. Lower room humidity was more common with positive surface samples and no 
significant differences were observed with other environmental measures.   
No viable virus could be recovered from any environmental sample that tested positive by PCR 
In total, 51/210 (24%) samples were positive or suspected-positive for viral RNA and were cultured. Only one 
nasopharyngeal sample from a HFNO participant (E gene Ct 21.99) could demonstrate presence of viable (infective) 
virus and all other samples, including environmental samples, were negative. This individual had two positive air 
samples that had higher Ct values for viral RNA and were culture negative.  
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DISCUSSION  
Our sampling study of the immediate environment of patients requiring non-invasive respiratory support for 
life-threatening COVID-19 disease found that few air and surface samples had measurable viral RNA contamination, 
irrespective of using CPAP/HFNO and/or coughing. Furthermore, the samples that did detect viral RNA by RT-qPCR, 
including those from the nasopharynx, failed to demonstrate biological viability in cell-culture except for one 
nasopharyngeal sample. These data question any significant additional risks to HCWs/other patients associated with 
the use of CPAP and HFNO which are considered ‘aerosol-generating’, compared to the use of supplemental oxygen. 
Consistent with other environmental sampling studies we found airborne and surface viral RNA 
contamination, 4% and 7% positive samples respectively, within the vicinity of COVID-19 patients although the degree 
of contamination is lower than that reported in most other studies12-20. This was despite the majority of our 
participants having detectable viral RNA in the nasopharynx at time of sampling and irrespective of respiratory 
support type and/or coughing. Importantly few previous studies included patients receiving non-invasive respiratory 
support, and from those that did there was little or no air contamination around NIV or HFNO19,16,18. Furthermore, 
our findings concur with other studies that report surface contamination is not associated with mode of respiratory 
support including HFNO and/or NIV12 17.  Consistent with others we found higher rates of floor contamination 
compared to other surfaces13 15. This is unsurprising given the likely cumulative deposition of virus laden droplets from 
the air combined with potential transference of the virus from footwear. Heterogeneity between clinical setting, study 
design and methodology limit direct comparisons and is likely to account for the variation in findings between studies. 
The lower degree of environmental contamination we found may be related to the stage of disease in our 
cohort of participants, with one sampling study reporting a decline in environmental contamination after the first 
week of illness13. Participants in our study were on average in their second week of illness when admitted to hospital 
(mean 9-days) and when sampled (mean 12-days). SARS-CoV-2 viral shedding is at its highest quantity in early 
infection and the peak of infectivity coincides with symptom onset before a gradual decline to near the detection limit 
by day 21, albeit with significant individual variability32-35. This kinetic is notably different to the related SARS-CoV-1 
virus where viral shedding peaks 7-10 days after symptom onset36 37, and coincides more with the time when patients 
are admitted for hospital care. The SARS outbreak was associated with a high incidence of healthcare worker and 
nosocomial transmission9. Although we found no significant relationship between nasopharyngeal viral load and days 
of illness (or environmental contamination), COVID-19 patients requiring non-invasive respiratory support are more 
likely to be at a stage of disease when it is plausible that host immunity has begun to establish control of viral shedding 
and infectivity.  
The levels of environmental contamination in our study were not significantly influenced by CPAP/HFNO 
therapies and/or coughing. These findings broadly reflect data from aerosol generation studies in healthy adult 
volunteers which report non-invasive positive pressure ventilation (NIPPV) and HFNO did not generate significantly 
more aerosols (compared to other respiratory activities)21 24 or in fact reduced emissions for NIPPV and HFNO22 and 
CPAP23. This may be influenced by the semi-closed system of CPAP delivery and PEEP over the nose and mouth 
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simultaneously that limit aerosol/droplet dispersion from respiratory secretions. High-flow nasal cannulae to deliver 
HFNO leaves the mouth open for potential expulsion of infective secretions. Hamilton et al report HFNO was 
associated with increased aerosol emission (flow rate and machine dependent), however this was generated by the 
machine, not the patient, hence unlikely to carry SARS-CoV-2 virus. Moreover, these studies consistently reported the 
highest aerosol emissions were from coughing, irrespective of respiratory support modality, with at least a 3-fold 
increase21-23. We did not find this signal in our data however these findings indicate that coughing is potentially the 
most hazardous source of infectious SARS-CoV-2 aerosols to HCWs and not the respiratory support device itself. The 
extrapolation of data from healthy volunteers may be limited to COVID-19 patients, however one study has shown 
that the aerosol particle size distribution is similar between the two populations23. Collectively, data from these 
studies and our own findings question whether the airborne mitigation measures are correctly aligned to the highest 
transmission risk, most likely from coughing and not the form of non-invasive respiratory support used.  
Importantly, we found no biologically viable virus in cell culture from any positive or suspected-positive   
environmental samples except for one nasopharyngeal sample from a HFNO participant (E gene Ct value 21.99). This 
was a common finding from other environmental sampling studies that attempted culture12 16 14 18 20. This may be due 
to air sampling methods which are known to inactivate viruses and impact upon virus infectivity38 39 although all of 
our surface and nasopharyngeal samples (except one) were also negative on cell culture. The stage of disease in our 
cohort of participants (mean 12-days of symptomatic illness at time of sampling) is likely to have influenced our 
findings, with one study demonstrating a median time of 7-days from symptom onset to viral clearance in culture, 
and the last positive culture being on day-1240. Furthermore, lower Ct values have been correlated with a higher 
likelihood of successful culture35 41 with studies demonstrating viable virus could only be cultured from clinical 
samples and experimentally contaminated surfaces if the Ct value <24 and <30 respectively16 42. All of our 
positive/suspected-positive environmental samples had a Ct value >30 and were likely to be below the detection 
threshold. This indicates that not only was there a poverty of viral RNA in the immediate environment of COVID-19 
patients receiving respiratory support therapies, but also there was no detectable viable virus present as an infection 
risk to HCWs.  
Our study has some notable strengths and limitations. Strengths include the ‘real-world’ setting, a 
standardised sampling strategy, concurrent air and surface sampling, collection of patient data and nasopharyngeal 
samples to understand the clinical context, and the use of human genetic material as a control. Finally, embedding 
the evaluation within the RECOVERY-Recovery Support randomised controlled trial helped to minimise selection bias. 
Limitations include the lack of serial sampling with findings representing a ‘snap shot’ picture, potential cross-
contamination by other infected patients in cohorted areas, no particle size fractionation or concentration 
measurement (hence not able to differentiate between droplets and aerosols), air volume sampled only a small 
fraction of the total room air and potential air leaks from the sides of CPAP masks not being captured by the air 
sampler. Additionally there are challenges in interpreting the significance of samples with low viral loads, and the 
extent to which PCR and viral culture technologies can be used as proxies for real world infectivity remains uncertain. 
The small group sizes risk the study being underpowered with confounding chance observations and larger studies are 
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needed to develop the evidence-base needed to reliably inform pragmatic infection prevention control measures 
around the use of CPAP/HFNO.  
Conclusions 
We found limited SARS-CoV-2 viral RNA within the immediate environment of hospitalised COVID-19 
patients and that this did not appear to be substantially influenced by the use of CPAP/HFNO devices or coughing, 
and importantly no detectable biologically viable virus. This adds to an increasing evidence base that in the context of 
COVID-19, CPAP and HFNO may not be higher transmission risk procedures that are associated with their ‘aerosol 
generating’ classification. Rather, HCW exposure and nosocomial transmission may be more influenced by patient 
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TABLES  
 
Table 1. The baseline clinical characteristics of study participants and the environment of care provision. 
 All SOC CPAP HFNO Statistically significant differences 
Number of participants 30 
 
10 10 10 - 
n Male gender  17 
 
6 5 6 - 












 Ethnicity      
 n Asian – Pakistani 10 2 6 2 - 
  n White -British 8 4 0 4 - 
 n Not given 4 1 3 0 - 
 n Asian - Indian 3 0 0 3 - 
 n Asian - Other 2 1 0 1 - 
 n White - Other 1 1 0 0 - 
 n Caribbean 1 1 0 0 - 
n Mixed – White and Caribbean 
 
1 0 1 0 - 
Mean number of days of illness at 
time of hospital admission  













Mean number of days of illness at 
time of sampling  











SOC vs CPAP p=ns (unpaired t-test) 
SOC vs HFNO p<0.01 (unpaired t-test) 
 
Median number of days in hospital at 












SOC vs CPAP p<0.01 (Mann-Whitney) 
SOC vs HFNO p<0.01 (Mann-Whitney) 
Mean number of days CPAP/HFNO at 
time of sampling  
[95% CI mean] (min-max) 
 



















Mean SpO2 at time of sampling 













 Room type      
 Open bay/cohort area 12 4 4 4 - 
Side room – ambient pressure 8 5 0 3 - 
Side room – negative pressure 7 0 6 1 - 
 Side room – natural airflow 
 
3 1 0 2 - 
Estimated air changes per hour (ACH)      
 10 ACH 15 6 6 6 - 
 4 to 6 ACH 10 4 4 2 - 
 4 ACH 
 
2 0 0 2 - 
Mean room air temperature (°C) at 
time of sampling 












SOC vs CPAP p=ns (unpaired t-test) 
SOC vs HFNO p<0.01 (unpaired t-test) 
 
Median room air CO2 content (ppm) 
















SOC vs CPAP p=0.02 (Mann-Whitney) 
SOC vs HFNO p=ns (Mann-Whitney) 
 
Mean room air humidity (%) at time 
of sampling 











SOC vs CPAP p=0.03 (unpaired t-test) 
SOC vs HFNO p=ns (unpaired t-test) 
n Receiving humidified oxygen 
 
15 6 2 7 - 
n CPAP full facemask (un-vented) 
 
n/a n/a 8 n/a - 
n CPAP partial facemask (vented) 
 
n/a n/a 2 n/a - 
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A total of 30 participants with moderate/severe COVID-19 were enrolled into the study. Paired t-tests were post-hoc 
analysis of differences between SOC and CPAP/HFNO study groups only. SOC, supplemental oxygen care. CPAP, 
continuous positive airway pressure. HFNO, high-flow nasal oxygen. FiO2, fraction of inspired oxygen. SpO2, oxygen 
saturation. CI, confidence interval. IQR, interquartile range. n/a, not applicable. ns, not significant. 
 
 All SOC CPAP HFNO 
Number of participants 
 
30 10 10 10 
 
Nasopharyngeal samples 
    
Number positive/suspected-positive/negative (overall % positive or suspected-positive) 












Overall for air samples 
















Air samples collected with participant breathing normally (SOC or CPAP/HFNO off)  
Number positive/suspected-positive/negative (overall % positive or suspected-positive) 



















Air samples collected with participant breathing normally (SOC or CPAP/HFNO on) 
Number positive/suspected-positive/negative (overall % positive or suspected-positive) 














Air samples collected with participant coughing every 2min (SOC or CPAP/HFNO on) 
Number positive/suspected-positive/negative (overall % positive or suspected-positive) 















Overall for surface samples 


















Number positive/suspected-positive/negative (overall % positive or suspected-positive) 



















Number positive/suspected-positive/negative (overall % positive or suspected-positive) 















Number positive/suspected-positive/negative (overall % positive or suspected-positive) 
















Table 2. The frequencies of SARS-CoV-2 RNA positive, suspected-positive and negative samples. 
A Ct value <45 for both the SARS-CoV-2 E gene and ORF1a gene was considered a positive result. A suspected positive 
result was recorded when only E or ORF1a Ct values were <45. A negative result was recorded when both E and ORF1a Ct 
values were ³45. Nasopharyngeal samples were collected according to local standard operating procedures and air 
samples and surfaces samples were collected per participant in accordance with the clinical study plan. There were no 
statistically significant differences in the Ct values of viral RNA in nasopharyngeal samples between study groups (p=ns, 
two-way ANOVA), and no statistically significant differences in the proportion of negative samples in each air and 
surface sample across the study groups (p=ns, Fisher’s exact). Alternative statistical tables are available in 
supplementary material. SOC, supplemental oxygen care. CPAP, continuous positive airway pressure. HFNO, high-flow 
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